Moreover, B2M-/- allogeneic MSCs showed better therapeutic effects than WT MSCs on myocardial infarction and hindlimb ischemia partly due to escaping from CD8+ T cell-mediated immune rejection in vivo7, 8. This evidence concerns the gene B2M and ischemia.